ES2107414T3 - Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis. - Google Patents

Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.

Info

Publication number
ES2107414T3
ES2107414T3 ES90104936T ES90104936T ES2107414T3 ES 2107414 T3 ES2107414 T3 ES 2107414T3 ES 90104936 T ES90104936 T ES 90104936T ES 90104936 T ES90104936 T ES 90104936T ES 2107414 T3 ES2107414 T3 ES 2107414T3
Authority
ES
Spain
Prior art keywords
erythropoyesis
stimulation
beta
human interferon
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90104936T
Other languages
English (en)
Inventor
Rita Michalevicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Interpharm Laboratories Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Interpharm Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Interpharm Laboratories Ltd filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of ES2107414T3 publication Critical patent/ES2107414T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE UTILIZA INTERFERON-BETA, PREFERIBLEMENTE EN DOSIS BAJAS, PARA LA ESTIMULACION DE LA ERITROPOYESIS EN DESORDENES CARACTERIZADOS PORQUE LAS CELULAS SANGUINEAS DEL PROGENITOR NO MADURAN COMO CELULAS ROJAS.
ES90104936T 1989-03-19 1990-03-15 Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis. Expired - Lifetime ES2107414T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL89662A IL89662A (en) 1989-03-19 1989-03-19 Pharmaceutical compositions comprising interferon-beta

Publications (1)

Publication Number Publication Date
ES2107414T3 true ES2107414T3 (es) 1997-12-01

Family

ID=11059803

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94112221T Expired - Lifetime ES2198409T3 (es) 1989-03-19 1990-03-15 Utilizacion del interferon-beta humano para la preparacion de composiciones farmaceuticas para el tratamiento de la leucemia mieloide cronica.
ES90104936T Expired - Lifetime ES2107414T3 (es) 1989-03-19 1990-03-15 Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94112221T Expired - Lifetime ES2198409T3 (es) 1989-03-19 1990-03-15 Utilizacion del interferon-beta humano para la preparacion de composiciones farmaceuticas para el tratamiento de la leucemia mieloide cronica.

Country Status (12)

Country Link
US (1) US5104653A (es)
EP (2) EP0643973B1 (es)
JP (1) JP2883669B2 (es)
AT (2) ATE240116T1 (es)
AU (1) AU619960B2 (es)
CA (1) CA2011992C (es)
DE (2) DE69031355T2 (es)
DK (2) DK0388799T3 (es)
ES (2) ES2198409T3 (es)
GR (1) GR3024763T3 (es)
IL (1) IL89662A (es)
ZA (1) ZA901994B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
JP4066460B2 (ja) * 1995-07-25 2008-03-26 東レ株式会社 骨疾患治療薬
US6239109B1 (en) 1998-02-09 2001-05-29 University Of Southern California Method of promoting erythropoiesis
HU228583B1 (en) * 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
WO2002040646A1 (en) * 2000-11-14 2002-05-23 Universite Libre De Bruxelles Generation and use of dendritic cells
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8084424B2 (en) * 2003-04-09 2011-12-27 University Of Utah Research Foundation Compositions and methods related to erythropoietin
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
AU2005239995A1 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
EP1984010A4 (en) * 2006-02-17 2010-09-08 Nitromed Inc METHOD FOR USE OF HYDRALAZIN COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
CA1294215C (en) * 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4851219A (en) * 1986-11-18 1989-07-25 Genentech, Inc. Method for the treatment of chronic myelogenous leukemia
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
CA2011992C (en) 2003-04-29
US5104653A (en) 1992-04-14
EP0643973A1 (en) 1995-03-22
IL89662A0 (en) 1989-09-28
JPH0314523A (ja) 1991-01-23
IL89662A (en) 1997-11-20
EP0388799B1 (en) 1997-09-03
DE69031355D1 (de) 1997-10-09
EP0643973B1 (en) 2003-05-14
ZA901994B (en) 1990-12-28
AU619960B2 (en) 1992-02-06
GR3024763T3 (en) 1997-12-31
CA2011992A1 (en) 1990-09-19
ATE240116T1 (de) 2003-05-15
DK0643973T3 (da) 2003-09-08
DE69034076T2 (de) 2003-11-20
ES2198409T3 (es) 2004-02-01
ATE157544T1 (de) 1997-09-15
DE69031355T2 (de) 1998-01-08
DK0388799T3 (da) 1998-03-30
DE69034076D1 (de) 2003-06-18
AU5144590A (en) 1990-09-20
EP0388799A3 (en) 1991-07-31
JP2883669B2 (ja) 1999-04-19
EP0388799A2 (en) 1990-09-26

Similar Documents

Publication Publication Date Title
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ES2147720T3 (es) Factor de celulas madre.
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
GR76810B (es)
IT8447957A1 (it) Composizione per rigenerare il collegamento del tessuto connettivo della pella, e suo procedimento di preparazione.
ES2068791T3 (es) Metodos y acido desoxirribonucleico para la preparacion de la proteina del factor tisular.
IT1138543B (it) L'applicazione in terapeutica dei derivati del 4,5,6,7-tetraidroisossazolo(5,4-c)piridin-3-olo come miotonolitici
ES290656Y (es) Dispositivo para recoger y mantener vivos los cultivos del cuerpo del paciente.
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
EP0151989A3 (en) Means for the treatment of cardiac diseases
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
IT1183181B (it) Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
SE8400723D0 (sv) Farmaceutisk komposition
MX9203409A (es) Proteinas bcrfi como inhibidores de la gama interferona.
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
DE69001686D1 (de) Behandlung von leukozytstoerungen mit gm-csf.
ES2080954T3 (es) Uso de beta-aletina en cultivos de celulas y en terapia.
IT7826263A0 (it) Derivati del piranocromone e composizione terapeutica comprendente gli stessi, per il trattamento di malattie allergiche.
IT1060117B (it) 4 alchil diossi alchilen 5 benzil pirimidine, procedimento per la loro preparazione e preparati medicinali
SE7901863L (sv) Medicinsk behandlingsstol, isynnerhet tandlekarstol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 388799

Country of ref document: ES